Beta Bionics, Inc. (BBNX) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of Beta Bionics, Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBNX
Beta Bionics, Inc.
$18.95HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.27HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBNX vs GLUE
growth of $100 · dividends reinvested · last 2yBBNX -19.8% (-10.4%/yr)GLUE +59.2% (+26.2%/yr)GLUE compounded faster over this window
BBNX GLUE
BBNX vs GLUE: by the numbers
- •GLUE is the larger company ($868M vs $853M market cap).
- •Both run net losses; BBNX's is the smaller (-61.32% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | BBNX | GLUE |
|---|---|---|
| P/S ratio | 7.16 | 30.20 |
| P/B ratio | 3.33 | 1.78 |
Profitability
| Metric | BBNX | GLUE |
|---|---|---|
| Gross margin | 58.31% | 92.94% |
| Operating margin | -69.75% | -43.83% |
| Net margin | -61.32% | -560.85% |
| ROE | -28.46% | -33.06% |
| ROIC | -31.17% | -28.69% |
Growth (annualized)
| Metric | BBNX | GLUE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -12.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.